Scientific Program

Filter Results:

Show Only CME Accredited Sessions

  • +

    MS16 - Implementation of Lung Cancer Screening

    • Type: Mini Symposium
    • Track: Screening and Early Detection
    • +

      MS16.01 - CMS Approved ACR Lung Cancer Screening Registry in the United States

      13:30 - 13:45  |  Presenting Author(s): Ella Kazerooni

      • Abstract

      Abstract not provided

    • +

      MS16.02 - NELCIN B3 Screening Program in China

      13:45 - 14:00  |  Presenting Author(s): Qinghua Zhou

      • Abstract

      Abstract not provided

    • +

      MS16.03 - Recruitment Strategies for the Lung Cancer Screening

      14:00 - 14:15  |  Presenting Author(s): Gail Elizabeth Darling

      • Abstract

      Abstract not provided

    • +

      MS16.04 - National Lung Screening Program in Taiwan

      14:15 - 14:30  |  Presenting Author(s): Pan-Chyr Yang

      • Abstract

      Abstract not provided

    • +

      MS16.05 - Optimal Approach to Integrate Smoking Cessation into Screening Program

      14:30 - 14:45  |  Presenting Author(s): Matthew Eric Callister

      • Abstract

      Abstract not provided

    • +

      MS16.06 - Q&A

      14:45 - 15:00

      • Abstract

      Abstract not provided

  • +

    MS17 - Life After Lung Cancer: Survivorship

    • Type: Mini Symposium
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • +

      MS17.01 - Unmet needs and QOL of Lung Cancer Survivors

      13:30 - 13:45  |  Presenting Author(s): Meredith Giuliani

      • Abstract

      Abstract not provided

    • +

      MS17.02 - Financial Toxicity and Out of Pocket Costs

      13:45 - 14:00  |  Presenting Author(s): Bishal Gyawali

      • Abstract

      Abstract not provided

    • +

      MS17.03 - Surveillance & Second Primary Malignancies in Lung Cancer Survivors

      14:00 - 14:15  |  Presenting Author(s): Virginie Westeel

      • Abstract

      Abstract not provided

    • +

      MS17.04 - How Important Is Tobacco Cessation as Part of Lung Cancer Treatment?

      14:15 - 14:30  |  Presenting Author(s): Clarissa Baldotto

      • Abstract

      Abstract not provided

    • +

      MS17.05 - Discussion

      14:30 - 15:00

      • Abstract

      Abstract not provided

  • +

    MS18 - Management of SCLC Patients Not Represented in Clinical Trials

    • Type: Mini Symposium
    • Track: Small Cell Lung Cancer/NET
    • +

      MS18.01 - Treatment of Patients with Poor Performance Status (ECOG 3-4)

      13:30 - 13:50  |  Presenting Author(s): Luiz H. Araujo

      • Abstract

      Abstract not provided

    • +

      MS18.02 - Treatment of Elderly Patients with SCLC

      13:50 - 14:10  |  Presenting Author(s): Karen Kelly

      • Abstract

      Abstract not provided

    • +

      MS18.03 - Treatment of SCLC transformed from EGFR Mutant Adenocarcinoma

      14:10 - 14:30  |  Presenting Author(s): Nicolas Marcoux

      • Abstract

      Abstract not provided

    • +

      MS18.04 - Retreatment with Platinum and Etoposide and Treatment Beyond Second Line

      14:30 - 14:50  |  Presenting Author(s): Charles Butts

      • Abstract

      Abstract not provided

    • +

      MS18.05 - Q&A

      14:50 - 15:00

      • Abstract

      Abstract not provided

  • +

    MS19 - Pulmonary Dilemmas with Immunotherapy

    • Type: Mini Symposium
    • Track: Interventional Diagnostics/Pulmonology
    • +

      MS19.01 - Drug-Induced Pneumonitis with IO: How worried should we be for our Lung Cancer Patients

      13:30 - 13:50  |  Presenting Author(s): Desiree Hao

      • Abstract

      Abstract not provided

    • +

      MS19.02 - What Are the Clinical Features of IO Progression/Pseudoprogression and Radiation Fibrosis vs Recurrence

      13:50 - 14:10  |  Presenting Author(s): Chong-Kin Liam

      • Abstract

      Abstract not provided

    • +

      MS19.03 - Diagnostic Approaches Suspected IO Progression/Pseudoprogression and What/When to Rebiospy for TT Progression

      14:10 - 14:30  |  Presenting Author(s): Kasia Czarnecka-Kujawa

      • Abstract

      Abstract not provided

    • +

      MS19.04 - Q&A

      14:30 - 15:00

      • Abstract

      Abstract not provided

  • +

    OA11 - Thymic and Other Thoracic Tumours: Targeted Therapies, Biomarkers and Neo/Adjuvant Radiotherapy

    • Type: Oral Abstract Session
    • Track: Thymoma/Other Thoracic Malignancies
  • +

    PC06 - Controversies in Immunobiomarker Testing

    • Type: Pro-Con Session
    • Track: Pathology
    • +

      PC06.01 - Laboratory Developed Test - PRO

      13:30 - 13:50  |  Presenting Author(s): Dara L. Aisner

      • Abstract

      Abstract not provided

    • +

      PC06.02 - Laboratory Developed Test - CON

      13:50 - 14:10  |  Presenting Author(s): Mari Mino-Kenudson

      • Abstract

      Abstract not provided

    • +

      PC06.03 - Tumor Mutation Burden - PRO

      14:10 - 14:30  |  Presenting Author(s): Lynette M Sholl

      • Abstract

      Abstract not provided

    • +

      PC06.04 - Tumor Mutation Burden - CON

      14:30 - 14:50  |  Presenting Author(s): Lukas Bubendorf

      • Abstract

      Abstract not provided

    • +

      PC06.05 - Q&A

      14:50 - 15:00

      • Abstract

      Abstract not provided

  • +

    PC07 - The Future of Cytotoxic Chemotherapy in Advanced NSCLC

    • Type: Pro-Con Session
    • Track: Advanced NSCLC
    • +

      PC07.03 - Debate 1: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO Alone versus Chemo + IO - IO Alone

      13:30 - 13:50  |  Presenting Author(s): Leora Horn

      • Abstract

      Abstract not provided

    • +

      PC07.04 - Debate 1: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO Alone versus Chemo + IO - Chemo + IO

      13:50 - 14:10  |  Presenting Author(s): Federico Cappuzzo

      • Abstract

      Abstract not provided

    • +

      PC07.01 - Debate 2: Chemotherapy Will Become a Thing of the Past in the Management of Advanced NSCLC - For

      14:10 - 14:30  |  Presenting Author(s): Suresh S. Ramalingam

      • Abstract

      Abstract not provided

    • +

      PC07.02 - Debate 2: Chemotherapy Will Become a Thing of the Past in the Management of Advanced NSCLC - Against

      14:30 - 14:50  |  Presenting Author(s): Keunchil Park

      • Abstract

      Abstract not provided

    • +

      PC07.05 - Q&A

      14:50 - 15:00

      • Abstract

      Abstract not provided

  • +

    PC08 - The Great Oligometastatic Debates

    • Type: Pro-Con Session
    • Track: Oligometastatic NSCLC
    • +

      PC08.01 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastese (PRO)

      13:30 - 13:40  |  Presenting Author(s): Howard West

      • Abstract

      Abstract not provided

    • +

      PC08.02 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastese (CON)

      13:40 - 13:50  |  Presenting Author(s): Puneeth Iyengar

      • Abstract

      Abstract not provided

    • +

      PC08.03 - Discussion

      13:50 - 14:00

      • Abstract

      Abstract not provided

    • +

      PC08.04 - Debate #2: Optimal Therapy for OM Disease: Thoracic Surgery Should Be the Treatment of Choice Whenever Possible

      14:00 - 14:10  |  Presenting Author(s): David R. Jones

      • Abstract

      Abstract not provided

    • +

      PC08.05 - Debate #2: Keep Calm and Beam On: Thoracic Radiation Obviates the Need for Surgery

      14:10 - 14:20  |  Presenting Author(s): Matthias Guckenberger

      • Abstract

      Abstract not provided

    • +

      PC08.06 - Discussion

      14:20 - 14:30

      • Abstract

      Abstract not provided

    • +

      PC08.07 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (PRO)

      14:30 - 14:40  |  Presenting Author(s): Mark K. Doherty

      • Abstract

      Abstract not provided

    • +

      PC08.08 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (CON)

      14:40 - 14:50  |  Presenting Author(s): Marta Scorsetti

      • Abstract

      Abstract not provided

    • +

      PC08.09 - Discussion

      14:50 - 15:00

      • Abstract

      Abstract not provided

  • +

    ES03 - How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy

    • Type: Educational Session
    • Track: Mesothelioma
  • +

    ES04 - Liquid Biopsies in Lung Cancer

    • Type: Educational Session
    • Track: Targeted Therapy
    • +

      ES04.01 - Liquid Biopsies in Lung Cancer

      15:20 - 15:40  |  Presenting Author(s): Ming Sound Tsao

      • Abstract

      Abstract not provided

    • +

      ES04.02 - Mechanisms of Resistance to Targeted Therapy

      15:40 - 16:00  |  Presenting Author(s): Christine Lovly

      • Abstract

      Abstract not provided

    • +

      ES04.04 - Guiding Second Line Treatment in ALK + Patients (Sequence of Drugs, Rebiopsy?)

      16:20 - 16:40  |  Presenting Author(s): Enriqueta Felip

      • Abstract

      Abstract not provided

    • +

      ES04.03 - Overcoming Resistance by Improving Treatment Compliance

      16:00 - 16:20  |  Presenting Author(s): Felipe Gomes

      • Abstract

      Abstract not provided

    • +

      ES04.05 - Q&A

      16:40 - 16:45

      • Abstract

      Abstract not provided

    • +

      ES04.00 - Introduction with Poll Questions

      15:15 - 15:20  |  Presenting Author(s): Sai-Hong Ignatius Ou, Ignacio I. Wistuba

      • Abstract

      Abstract not provided